Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Recurrence × Trabectedin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 6 Sarcoma 5 Liposarcoma 4 Leiomyosarcoma 3 Neoplasms 2 Fallopian Tube Neoplasms 2 Sarcoma, Ewing 1 Recurrent High Grade Meningioma 1 Recurrence 1 Prostatic Neoplasms 1 Peritoneal Neoplasms 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neoplasm Metastasis 1 Liposarcoma, Myxoid 1 Carcinoma, Ovarian Epithelial 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 32 Dexamethasone 30 Rituximab 22 Cytarabine 21 fludarabine phosphate 20 Methotrexate 17 Lenalidomide 17 fludarabine 15 Bortezomib 15 Peripheral Blood Stem Cell Transplantation 14 Calcium Dobesilate 14 Whole-Body Irradiation 13 Mycophenolic Acid 13 Etoposide 13 pembrolizumab 12 Melphalan 12 Filgrastim 12 Paclitaxel 11 Gemcitabine 11 Cyclosporine 11 Carboplatin 11 pomalidomide 10 Busulfan 10 Vincristine 9 carfilzomib 8 Tacrolimus 8 Panobinostat 8 Clofarabine 8 Cetuximab 8 Brentuximab Vedotin 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03164980 2025-03-20

COMPASS

North Eastern German Society of Gynaecological Oncology

Phase 4 Terminated

89 enrolled 20 charts

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡